Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.Aleksandra Franovic, Eric S. Martin, Sean Uryu et al.|Journal of Clinical Oncology|2022Cited by 8